PremiumThe FlyXBiotech trading halted, news pending XBiotech announces data from Phase 1/2 1-BETTER study PremiumThe FlyXBiotech announces enrollment completion of Phase II study for Natrunix XBiotech treats first patient in Phase II RA trial of Natrunix XBiotech announces first subject enrollment in Phase I trial for Hutrukin